Assessment of Homologous Recombination Deficiency in Ovarian Cancer.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 37347464.
- Also identified by DOI 10.1158/1078-0432.CCR-23-0563.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Accurately assessing homologous recombination deficiency (HRD) to use as a predictive biomarker is an area of intense research in ovarian cancer. Validated assays have demonstrated utility in determining maintenance therapy following platinum sensitive chemotherapy. Novel functional assays promise the potential to reflect HRD in real time and predict response to PARP inhibitors. See related articles by Pikkusaari et al., p. 3110 and Blanc-Durand et al., p. 3124.
Medical subject headings
- Ovarian Neoplasms